Global Human Fibrinogen Sales Market Report 2020
Fibrinogen (factor I) is a glycoprotein in vertebrates that helps in the formation of blood clots. Human Fibrinogen is used as a medicine for blood disease. Human Fibrinogen is a preparation of coagulation factors prepared from pooled plasma. Currently, only RiaSTAP (CSL Behring) is licensed in a number of countries for multiple indications including treating acute bleeding episodes with Hypofibrinogenemia. Other manufacturer’s products are justly used in local region or countries.
By product, the global Human Fibrinogen market is segmented into animal Fibrinogen and Human Fibrinogen Concentrate. Animal fibrinogen is still studying to confirm whether it produce toxic effect on human tissues or not after injection, it accounts for majority 0.47% market share of global revenue and Human Fibrinogen Concentrate accounts for majority 99.53% market share of global revenue in 2019.
By end user, the global Human Fibrinogen market is segmented into congenital fibrinogen deficiency and surgical procedures. In 2019, the Surgical Procedures application held the largest share in the global market and accounted for a market share of 91.74%. The Surgical Procedures is major segmented into trauma patients, cardiovascular surgery patients, PPH patients, and plastic surgery patients, accounting for 62.85%, 10.34%, 13.71%, and 1.31% respectively.
CSL is the leaders of the industry, with 52.52% market share of value in 2019, 32.44% market share of volume in 2019 and hold key technologies and patents. Other manufactures’ products are used to meet local demand. With further expanding market, there will be more players in the future.
Market Analysis and Insights: Global Human Fibrinogen Market
The global Human Fibrinogen market size is projected to reach US$ 1635.7 million by 2026, from US$ 689 million in 2020, at a CAGR of 15.5% during 2021-2026.
Global Human Fibrinogen Scope and Market Size
The global Human Fibrinogen market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Human Fibrinogen market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2015-2026.
Segment by Type, the Human Fibrinogen market is segmented into
Pure Human Fibrinogen
Fibrinogen Concentrate (Human)
Segment by Application, the Human Fibrinogen market is segmented into
Congenital Fibrinogen Deficiency
Surgical Procedures
The Human Fibrinogen market is analysed and market size information is provided by regions (countries). Segment by Application, the Human Fibrinogen market is segmented into United States, Europe, China, Japan, Southeast Asia, India and Rest of World.
The report includes region-wise market size for the period 2015-2026. It also includes market size and forecast by players, by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Human Fibrinogen market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Human Fibrinogen business, the date to enter into the Human Fibrinogen market, Human Fibrinogen product introduction, recent developments, etc.
The major vendors covered:
CSL Behring
LFB Group
Shanghai RAAS Blood Products
Jiangxi Boya Bio-Pharmaceutical
Hualan Biological Engineering
Harbin Pacific Biopharmaceutical
GREEN CROSS
Shanghai XinXing Medical
Octapharma
By product, the global Human Fibrinogen market is segmented into animal Fibrinogen and Human Fibrinogen Concentrate. Animal fibrinogen is still studying to confirm whether it produce toxic effect on human tissues or not after injection, it accounts for majority 0.47% market share of global revenue and Human Fibrinogen Concentrate accounts for majority 99.53% market share of global revenue in 2019.
By end user, the global Human Fibrinogen market is segmented into congenital fibrinogen deficiency and surgical procedures. In 2019, the Surgical Procedures application held the largest share in the global market and accounted for a market share of 91.74%. The Surgical Procedures is major segmented into trauma patients, cardiovascular surgery patients, PPH patients, and plastic surgery patients, accounting for 62.85%, 10.34%, 13.71%, and 1.31% respectively.
CSL is the leaders of the industry, with 52.52% market share of value in 2019, 32.44% market share of volume in 2019 and hold key technologies and patents. Other manufactures’ products are used to meet local demand. With further expanding market, there will be more players in the future.
Market Analysis and Insights: Global Human Fibrinogen Market
The global Human Fibrinogen market size is projected to reach US$ 1635.7 million by 2026, from US$ 689 million in 2020, at a CAGR of 15.5% during 2021-2026.
Global Human Fibrinogen Scope and Market Size
The global Human Fibrinogen market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Human Fibrinogen market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2015-2026.
Segment by Type, the Human Fibrinogen market is segmented into
Pure Human Fibrinogen
Fibrinogen Concentrate (Human)
Segment by Application, the Human Fibrinogen market is segmented into
Congenital Fibrinogen Deficiency
Surgical Procedures
The Human Fibrinogen market is analysed and market size information is provided by regions (countries). Segment by Application, the Human Fibrinogen market is segmented into United States, Europe, China, Japan, Southeast Asia, India and Rest of World.
The report includes region-wise market size for the period 2015-2026. It also includes market size and forecast by players, by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape
and Human Fibrinogen Market Share AnalysisHuman Fibrinogen market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Human Fibrinogen business, the date to enter into the Human Fibrinogen market, Human Fibrinogen product introduction, recent developments, etc.
The major vendors covered:
CSL Behring
LFB Group
Shanghai RAAS Blood Products
Jiangxi Boya Bio-Pharmaceutical
Hualan Biological Engineering
Harbin Pacific Biopharmaceutical
GREEN CROSS
Shanghai XinXing Medical
Octapharma
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
Please Select a Format
